VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2, VEGFR-2, FLK-1, KDR) (VEGFR2, VEGFR 2, Protein-tyrosine kinase receptor flk-1, Fetal liver kinase 1, Kinase NYK, FLK1, KDR, Kinase insert domain receptor, KRD1, Ly73, Protein

Catalog Number: USB-V2110-18F-ML490
Article Name: VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2, VEGFR-2, FLK-1, KDR) (VEGFR2, VEGFR 2, Protein-tyrosine kinase receptor flk-1, Fetal liver kinase 1, Kinase NYK, FLK1, KDR, Kinase insert domain receptor, KRD1, Ly73, Protein
Biozol Catalog Number: USB-V2110-18F-ML490
Supplier Catalog Number: V2110-18F-ML490
Alternative Catalog Number: USB-V2110-18F-ML490-100
Manufacturer: US Biological
Host: Rabbit
Category: Antikörper
Application: FLISA, WB
Immunogen: Synthetic peptide derived from the N-terminal region of the mouse vascular endothelial growth factor receptor-2 (VEGFR-2, FLK-1, KDR) protein.
MaxLight(TM) 490 is a new Blue-Green photostable dye conjugate comparable to DyLight(TM)488, Alexa Fluor(TM)488 and offers better labeling efficiency, brighter imaging and increased immunodetection. Absorbance (491nm), Emission (515nm), Extinction Coefficient 73,000. Vascular endothelial growth factor receptor-2 (VEGFR-2), also known as fetal liver kinase 1 (FLK-1) in mouse and KDR in human, is a transmembrane tyrosine kinase that plays an important role in the development of the vascular system and the vascularization of a wide variety of tumors. Binding of VEGF to VEGFR-2 leads to tyrosine phosphorylation of the dimerized receptor and subsequent phosphorylation of SH2-containing intracellular signaling proteins, including phospholipase C, Src family tyrosine kinase and phosphatidylinositol 3-kinase (PI3K) adaptor molecules, SHC, NCK, and Ras GTPase-activating protein. VEGFR-2 is expressed in cultured human umbilical vein endothelial cells (HUVEC), Hela cells, WM 35 melanoma cells, WM 9 melanoma cells, as well as mouse NIH3T3, and Balb/c 3T3 cells. In a single study of 115 paraffin-embedded cancer specimens analyzed by immunohistochemistry, VEGFR-2 expression was observed in bladder tumors, breast cancer, intestinal cancer and lung cancer, suggesting a direct role for VEGF as an autocrine growth factor in a variety of human cancers. Applications: Suitable for use in FLISA and Western Blot. Other applications not tested. Recommended Dilution: FLISA: 0.1-1ug/ml Western Blot: 1-5ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: Store product at 4C in the dark. DO NOT FREEZE! Stable at 4C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight(TM)490 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Note: Applications are based on unconjugated antibody.
Purity: Purified by immunoaffinity chromatography.
Form: Supplied as a liquid in PBS, pH 7.2. No preservatives added. Labeled with MaxLight(TM)490.